Duality Biotherapeutics Valuation Multiples

Duality Biotherapeutics Overview

About Duality Biotherapeutics

Duality Biotherapeutics Inc is a key player in the antibody-drug conjugate (ADC) landscape, dedicated to the development of inventive therapeutics in this fast-growing drug modality to treat cancer, autoimmune diseases, and beyond. Its pipeline of 12 in-house discovered ADC candidates is a testament to its prowess in ADC innovation, comprising: (i) seven clinical-stage ADCs with potential in a broad range of indications, two next-generation bispecific ADCs, and multiple other preclinical ADCs. Its Products DB-1303/BNT323 and DB-1311/BNT324 and key product DB-1305/BNT325, have received Fast Track Designation. DB-1303 is a late clinical-stage HER2 ADC candidate with two ongoing registrational trials and one potential global registrational study.

Founded

2019

HQ

Employees

191

Website

dualitybiologics.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $262M

EBITDA: ($67M)

EV

$3B

Valuation Multiples

Multiples.vc

Start free trial

Duality Biotherapeutics Financials

Duality Biotherapeutics reported last 12-month revenue of $262M and negative EBITDA of ($67M).

In the same LTM period, Duality Biotherapeutics generated $90M in gross profit, ($67M) in EBITDA losses, and had net loss of ($290M).

Duality Biotherapeutics P&L

In the most recent fiscal year, Duality Biotherapeutics reported revenue of $284M and EBITDA of ($147M).

Duality Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Duality Biotherapeutics Stock Performance

Duality Biotherapeutics has current market cap of $3B, and enterprise value of $3B.

Duality Biotherapeutics' stock price is $38.71.

Duality Biotherapeutics Valuation Multiples

Duality Biotherapeutics trades at 11.2x EV/Revenue multiple, and (44.1x) EV/EBITDA.

Duality Biotherapeutics Financial Valuation Multiples

As of April 11, 2026, Duality Biotherapeutics has market cap of $3B and EV of $3B.

Equity research analysts estimate Duality Biotherapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Duality Biotherapeutics has a P/E ratio of (11.7x).

Duality Biotherapeutics Margins & Growth Rates

Duality Biotherapeutics' revenue in the last 12 month declined by (7%).

Duality Biotherapeutics' revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $0.7M for the same period.

Duality Biotherapeutics' rule of 40 is (33%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Duality Biotherapeutics' rule of X is (46%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Duality Biotherapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Duality Biotherapeutics M&A Activity

Duality Biotherapeutics acquired XXX companies to date.

Last acquisition by Duality Biotherapeutics was on XXXXXXXX, XXXXX. Duality Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Duality Biotherapeutics Investment Activity

Duality Biotherapeutics invested in XXX companies to date.

Duality Biotherapeutics made its latest investment on XXXXXXXX, XXXXX. Duality Biotherapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).